A Randomized, Active-controlled, Double-blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated ATB-1011 and ATB-1012 in Patients With Essential Hypertension and Type II Diabetes Mellitus
Latest Information Update: 06 Feb 2023
At a glance
- Drugs Dapagliflozin/olmesartan medoxomil (Primary)
- Indications Essential hypertension; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Autotelic Bio
Most Recent Events
- 14 Oct 2022 Status changed from not yet recruiting to recruiting.
- 11 Oct 2022 New trial record